{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:16:09Z","timestamp":1783340169704,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,4]],"date-time":"2027-06-04T00:00:00Z","timestamp":1812067200000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019399","name":"Viracor Eurofins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcyt.2026.102878","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:27:23Z","timestamp":1775575643000},"page":"102878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipients"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4588-3049","authenticated-orcid":false,"given":"Swarn","family":"Arya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-5548","authenticated-orcid":false,"given":"Rich","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuri","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ulloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1070","authenticated-orcid":false,"given":"Evangelos","family":"Ntrivalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kleiboeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-079X","authenticated-orcid":false,"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102878_bib0001","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102878_bib0002","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0003","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102878_bib0004","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European conference on infections in leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101092","article-title":"Does PTCY increase the risk of infections?","volume":"62","author":"Mikulska","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2026.102878_bib0006","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41409-023-01944-2","article-title":"CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality","volume":"58","author":"Eberhardt","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102878_bib0007","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/bloodadvances.2023012175","article-title":"Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques","volume":"8","author":"Sadowska-Klasa","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102878_bib0008","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102878_bib0009","doi-asserted-by":"crossref","first-page":"e14377","DOI":"10.1111\/tid.14377","article-title":"Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed-onset clinically significant cytomegalovirus infection after letermovir prophylaxis?","volume":"26","author":"Mendoza","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106044","article-title":"Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients","volume":"9","author":"Gabanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102878_bib0011","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2005.07.008","article-title":"Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection","volume":"11","author":"Gallez-Hawkins","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102878_bib0012","first-page":"367","article-title":"The terminase complex, a relevant target for the treatment of HCMV infection","volume":"36","author":"Ligat","year":"2020","journal-title":"Med Sci"},{"key":"10.1016\/j.jcyt.2026.102878_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13619","article-title":"Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis","volume":"23","author":"Chen","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102878_bib0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jtct.2021.03.003","article-title":"Cytomegalovirus prophylaxis versus pre-emptive strategy: different CD4+ and CD8+ T cell reconstitution after allogeneic hematopoietic stem cell transplantation: CMV pre-emptive treatment versus prophylaxis","volume":"27","author":"Sperotto","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102878_bib0016","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41409-023-02046-9","article-title":"Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir","volume":"58","author":"Orofino","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102878_bib0017","doi-asserted-by":"crossref","first-page":"e14021","DOI":"10.1111\/tid.14021","article-title":"Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir","volume":"25","author":"Gim\u00e9nez","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102878_bib0019","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0020","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0021","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtct.2023.03.018","article-title":"Immunologic monitoring after allogeneic stem cell transplantation: T-SPOT.CMV and QuantiFERON-CMV, are they the same?","volume":"29","author":"Callens","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102878_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12865-017-0195-y","article-title":"An optimized IFN-gamma ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity","volume":"18","author":"Barabas","year":"2017","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jcyt.2026.102878_bib0023","article-title":"Immune reconstitution of human cytomegalovirus-specific T lymphocytes after allogeneic hematopoietic stem cell transplantation and their predictive role in reactivation","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102878_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad386","article-title":"Impact of baseline and week 2 and week 4 posttransplant CMV cell-mediated immunity on risk of CMV infections and mortality in recipients of allogeneic hematopoietic cell transplant","volume":"10","author":"Ariza-Heredia","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0025","doi-asserted-by":"crossref","first-page":"41154","DOI":"10.1038\/s41598-025-27490-z","article-title":"Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT","volume":"15","author":"Duplessix","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102878_bib0026","article-title":"Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14290","article-title":"Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: a pilot study","volume":"26","author":"Jacobs","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0028","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0029","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1200\/JCO.2024.42.16_suppl.6503","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"42","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102878_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/10428194.2014.930851","article-title":"Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant","volume":"56","author":"Ceberio","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2026.102878_bib0031","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbmt.2019.10.003","article-title":"Ex vivo T cell-depleted hematopoietic stem cell transplantation for adult patients with acute myelogenous leukemia in first and second remission: long-term disease-free survival with a significantly reduced risk of graft-versus-host disease","volume":"26","author":"Montoro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102878_bib0032","series-title":"Abstract Book of the 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases","first-page":"27","article-title":"Correlation of Cytomegalovirus specific cell mediated immunity (CMV CMI) with subclinical CMV DNAemia in allogenic hematopoietic cell transplant recipients (HCT)","author":"Kodama","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102878_bib0033","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102878_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193968","article-title":"Assessment of the T-SPOT.CMV interferon-gamma release assay in renal transplant recipients: a single center cohort study","volume":"13","author":"Chanouzas","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102878_bib0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189488","article-title":"Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102878_bib0037","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2019.229252","article-title":"Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation","volume":"106","author":"Wagner-Drouet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102878_bib0038","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","article-title":"American society for transplantation and cellular therapy series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients","volume":"31","author":"Khawaja","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102878_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14437","article-title":"Diagnostic performance of two different techniques to quantify CMV-specific cell-mediated immunity in intermediate-risk seropositive kidney transplant recipients","volume":"28","author":"Fernandez-Ruiz","year":"2026","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0040","first-page":"ciaf646","article-title":"An analysis of cytomegalovirus-specific cell-mediated immunity in a phase 3, randomized, placebo-controlled trial of letermovir prophylaxis in cytomegalovirus-seropositive recipients of an allogeneic hematopoietic cell transplant","author":"Papanicolaou","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0041","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41409-025-02611-4","article-title":"ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients","volume":"60","author":"Zamora","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102878_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246191","article-title":"Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients","volume":"16","author":"Seo","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102878_bib0043","doi-asserted-by":"crossref","first-page":"e70152","DOI":"10.1111\/tid.70152","article-title":"QuantiFERON-CMV monitoring post-allogeneic hematopoietic stem cell transplantation is dynamic and predictive of immediate cytomegalovirus outcomes","volume":"28","author":"Sim","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2026.102878_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2026.102344","article-title":"Recovery of CMV immunity after allogeneic haematopoietic stem cell transplant\u2014insight from an in-depth analysis of a small cohort of patients with clinical correlation","volume":"94","author":"Linn","year":"2026","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jcyt.2026.102878_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102878_bib0046","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2022.280685","article-title":"Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Tassi","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102878_bib0047","first-page":"1081","article-title":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era","volume":"111","author":"Tassi","year":"2026","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600839X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600839X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:26:07Z","timestamp":1783337167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600839X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S146532492600839X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102878","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipients","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102878"}}